Home/Filings/4/0001567619-21-001343
4//SEC Filing

Rousseau Raphael 4

Accession 0001567619-21-001343

CIK 0001656634other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 5:11 PM ET

Size

14.6 KB

Accession

0001567619-21-001343

Insider Transaction Report

Form 4
Period: 2021-01-19
Rousseau Raphael
See Remarks
Transactions
  • Exercise/Conversion

    Common Stock

    2021-01-19$0.76/sh+20,000$15,20020,000 total
  • Exercise/Conversion

    Common Stock

    2021-01-20$0.76/sh+10,000$7,60010,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-01-1920,000135,326 total
    Exercise: $0.76Exp: 2027-05-17Common Stock (20,000 underlying)
  • Sale

    Common Stock

    2021-01-19$17.53/sh20,000$350,5640 total
  • Sale

    Common Stock

    2021-01-20$25.07/sh10,000$250,7050 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-01-2010,000125,326 total
    Exercise: $0.76Exp: 2027-05-17Common Stock (10,000 underlying)
Footnotes (4)
  • [F1]The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
  • [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $15.00 to $20.04 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.00 to $25.17 per share. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  • [F4]The stock option vests and becomes exercisable with respect to 25% of the total number of shares on April 17, 2018. The remaining shares vest and become exercisable in equal monthly installments over the following 36 months.

Documents

1 file

Issuer

Gritstone Oncology, Inc.

CIK 0001656634

Entity typeother

Related Parties

1
  • filerCIK 0001754287

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 5:11 PM ET
Size
14.6 KB